Log in

Relevant bibliographies by topics / High-throughput drug screening / Journal articles

To see the other types of publications on this topic, follow the link: High-throughput drug screening.

Journal articles on the topic 'High-throughput drug screening'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'High-throughput drug screening.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Heemskerk, Jill. "High throughput drug screening." Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 5, sup1 (2004): 19–21. http://dx.doi.org/10.1080/17434470410019735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Grepin, Claudine, and Christine Pernelle. "High-throughput screening." Drug Discovery Today 5, no. 5 (2000): 212–14. http://dx.doi.org/10.1016/s1359-6446(00)01491-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shumate, Chris, Scott Beckey, Peter Coassin, and Harry Stylli. "Ultra-High Throughput Screening." Laboratory Automation News 2, no. 4 (1997): 24–29. http://dx.doi.org/10.1177/221106829700200406.

Full text

Abstract:

Aurora Biosciences Corporation designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new pharmaceuticals. Aurora is developing an integrated technology platform centered around two technologies; 1) a portfolio of proprietary fluorescent assay technologies and, 2) an ultra-high throughput screening (“UHTS”) system designed to allow assay miniaturization and to overcome many of the limitations associated with the traditional drug discovery process. This approach takes advantage of the opportunities created by recent advances

APA, Harvard, Vancouver, ISO, and other styles

4

Entzeroth, Michael, Béatrice Chapelain, Jacques Guilbert, and Valérie Hamon. "High throughput drug profiling." Journal of Automated Methods and Management in Chemistry 22, no. 6 (2000): 171–73. http://dx.doi.org/10.1155/s1463924600000304.

Full text

Abstract:

High throughput screening has significantly contributed to advances in drug discovery. The great increase in the number of samples screened has been accompanied by increases in costs and in the data required for the investigated compounds. High throughput profiling addresses the issues of compound selectivity and specificity. It combines conventional screening with data mining technologies to give a full set of data, enabling development candidates to be more fully compared.

APA, Harvard, Vancouver, ISO, and other styles

5

Segall, Matthew. "Smart high-throughput screening." Drug Discovery Today 8, no. 4 (2003): 160–61. http://dx.doi.org/10.1016/s1359-6446(03)02598-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Burbaum, Jonathan J. "Whither high-throughput screening?" Drug Discovery Today 5 (June 2000): 1–2. http://dx.doi.org/10.1016/s1359-6446(00)01482-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Carnero, Amancio. "High throughput screening in drug discovery." Clinical and Translational Oncology 8, no. 7 (2006): 482–90. http://dx.doi.org/10.1007/s12094-006-0048-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Williams, Gareth P. "Advances in high throughput screening." Drug Discovery Today 9, no. 12 (2004): 515–16. http://dx.doi.org/10.1016/s1359-6446(04)03099-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fomenko, Igor, Mark Durst, and David Balaban. "Robust regression for high throughput drug screening." Computer Methods and Programs in Biomedicine 82, no. 1 (2006): 31–37. http://dx.doi.org/10.1016/j.cmpb.2006.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ling, Xuefeng. "High Throughput Screening Informatics." Combinatorial Chemistry & High Throughput Screening 11, no. 3 (2008): 249–57. http://dx.doi.org/10.2174/138620708783877726.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hertzberg, Robert. "Centralized High Throughput Screening." Journal of Biomolecular Screening 1, no. 4 (1996): 177–78. http://dx.doi.org/10.1177/108705719600100403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Smith, Robert E., Kevin Tran, and Ralph H. Vocque. "Network Medicine and High Throughput Screening." Current Drug Discovery Technologies 10, no. 3 (2013): 182–94. http://dx.doi.org/10.2174/1570163811310030002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lutz, Michael W., J. Alan Menius, Tony D. Choi, et al. "Experimental design for high-throughput screening." Drug Discovery Today 1, no. 7 (1996): 277–86. http://dx.doi.org/10.1016/1359-6446(96)10025-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wan, Hong, and Fredrik Bergström. "High Throughput Screening of Drug‐Protein Binding in Drug Discovery." Journal of Liquid Chromatography & Related Technologies 30, no. 5-7 (2007): 681–700. http://dx.doi.org/10.1080/10826070701190989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Chi, Chun-Wei, AH Rezwanuddin Ahmed, Zeynep Dereli-Korkut, and Sihong Wang. "Microfluidic cell chips for high-throughput drug screening." Bioanalysis 8, no. 9 (2016): 921–37. http://dx.doi.org/10.4155/bio-2016-0028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Trubetskoy, Olga, Moshe Finel, and Vladimir Trubetskoy. "High-throughput screening technologies for drug glucuronidation profiling." Journal of Pharmacy and Pharmacology 60, no. 8 (2008): 1061–67. http://dx.doi.org/10.1211/jpp.60.8.0012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Maurer, Hans H., and Frank T. Peters. "Toward High-Throughput Drug Screening Using Mass Spectrometry." Therapeutic Drug Monitoring 27, no. 6 (2005): 686–88. http://dx.doi.org/10.1097/01.ftd.0000180224.19384.f0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Metz, Alexander, Franziska Huschmann, Johannes Schiebel, et al. "High-throughput crystallographic fragment screening for drug discovery." Acta Crystallographica Section A Foundations and Advances 74, a2 (2018): e24-e24. http://dx.doi.org/10.1107/s2053273318094858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bereau, Tristan. "Computational High-throughput Screening of Drug-Membrane Thermodynamics." Biophysical Journal 114, no. 3 (2018): 557a. http://dx.doi.org/10.1016/j.bpj.2017.11.3044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Liu, Jia, Kang Li, Lin Cheng, et al. "A high-throughput drug screening strategy against coronaviruses." International Journal of Infectious Diseases 103 (February 2021): 300–304. http://dx.doi.org/10.1016/j.ijid.2020.12.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Büttner, Frank H. "Cell-based assays for high-throughput screening." Expert Opinion on Drug Discovery 1, no. 4 (2006): 373–78. http://dx.doi.org/10.1517/17460441.1.4.373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

De Stefano, Paola, Elena Bianchi, and Gabriele Dubini. "The impact of microfluidics in high-throughput drug-screening applications." Biomicrofluidics 16, no. 3 (2022): 031501. http://dx.doi.org/10.1063/5.0087294.

Full text

Abstract:

Drug discovery is an expensive and lengthy process. Among the different phases, drug discovery and preclinical trials play an important role as only 5–10 of all drugs that begin preclinical tests proceed to clinical trials. Indeed, current high-throughput screening technologies are very expensive, as they are unable to dispense small liquid volumes in an accurate and quick way. Moreover, despite being simple and fast, drug screening assays are usually performed under static conditions, thus failing to recapitulate tissue-specific architecture and biomechanical cues present in vivo even in the

APA, Harvard, Vancouver, ISO, and other styles

23

Mayr, Lorenz M., and Peter Fuerst. "The Future of High-Throughput Screening." Journal of Biomolecular Screening 13, no. 6 (2008): 443–48. http://dx.doi.org/10.1177/1087057108319644.

Full text

Abstract:

High-throughput screening (HTS) is a well-established process in lead discovery for pharma and biotech companies and is now also being set up for basic and applied research in academia and some research hospitals. Since its first advent in the early to mid-1990s, the field of HTS has seen not only a continuous change in technology and processes but also an adaptation to various needs in lead discovery. HTS has now evolved into a quite mature discipline of modern drug discovery. Whereas in previous years, much emphasis has been put toward a steady increase in capacity (“quantitative increase”)

APA, Harvard, Vancouver, ISO, and other styles

24

Schmid, Ingrid, Isabel Sattler, Susanne Grabley, and Ralf Thiericke. "Natural Products in High Throughput Screening: Automated High-Quality Sample Preparation." Journal of Biomolecular Screening 4, no. 1 (1999): 15–25. http://dx.doi.org/10.1177/108705719900400104.

Full text

Abstract:

At present, compound libraries from combinatorial chemistry are the major source for high throughput screening (HTS) programs in drug discovery. On the other hand, nature has been proven to be an outstanding source for new and innovative drugs. Secondary metabolites from plants, animals, and microorganisms show a striking structural diversity that supplements chemically synthesized compounds or libraries in drug discovery programs. Unfortunately, extracts from natural sources are usually complex mixtures of compounds, often generated in time-consuming and, for the most part, manual processes.

APA, Harvard, Vancouver, ISO, and other styles

25

Jessen, Timm. "High-throughput screening brings in the crops." Drug Discovery Today 5 (January 2000): S49. http://dx.doi.org/10.1016/s1359-6446(00)80001-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Crouch, Sharon P. M., and Kevin J. Slater. "High-throughput cytotoxicity screening: hit and miss." Drug Discovery Today 6 (June 2001): 48–53. http://dx.doi.org/10.1016/s1359-6446(01)00151-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Szymański, Paweł, Magdalena Markowicz, and Elżbieta Mikiciuk-Olasik. "Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests." International Journal of Molecular Sciences 13, no. 1 (2011): 427–52. http://dx.doi.org/10.3390/ijms13010427.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ordas, Anita, Robert-Jan Raterink, Fraser Cunningham, et al. "Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen." Antimicrobial Agents and Chemotherapy 59, no. 2 (2014): 753–62. http://dx.doi.org/10.1128/aac.03588-14.

Full text

Abstract:

ABSTRACTThe translational value of zebrafish high-throughput screens can be improved when more knowledge is available on uptake characteristics of potential drugs. We investigated reference antibiotics and 15 preclinical compounds in a translational zebrafish-rodent screening system for tuberculosis. As a major advance, we have developed a new tool for testing drug uptake in the zebrafish model. This is important, because despite the many applications of assessing drug efficacy in zebrafish research, the current methods for measuring uptake using mass spectrometry do not take into account the

APA, Harvard, Vancouver, ISO, and other styles

29

Moyer, Paula. "HIGH THROUGHPUT DRUG SCREENING TO FIND NEW DRUGS FOR INTRACTABLE DISEASES." Neurology Today 3, no. 9 (2003): 36–37. http://dx.doi.org/10.1097/00132985-200309000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Fox, Sandra, Shauna Farr-Jones, Lynne Sopchak, et al. "High-Throughput Screening: Update on Practices and Success." Journal of Biomolecular Screening 11, no. 7 (2006): 864–69. http://dx.doi.org/10.1177/1087057106292473.

Full text

Abstract:

High-throughput screening (HTS) has become an important part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and use of HTS technologies is expanding into new areas. Target validation, assay development, secondary screening, ADME/Tox, and lead optimization are among the areas in which there is an increasing use of HTS technologies. It is becoming fully integrated within drug discovery, both upstream and downstream, which includes increasing use of cell-based assays and high-content screening (HCS) technologies to achieve more physiologically relevant result

APA, Harvard, Vancouver, ISO, and other styles

31

Siqueira-Neto, Jair L., Ok-Ryul Song, Hyunrim Oh, et al. "Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds." PLoS Neglected Tropical Diseases 4, no. 5 (2010): e675. http://dx.doi.org/10.1371/journal.pntd.0000675.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Prummer, Michael. "Hypothesis Testing in High-Throughput Screening for Drug Discovery." Journal of Biomolecular Screening 17, no. 4 (2012): 519–29. http://dx.doi.org/10.1177/1087057111431278.

Full text

Abstract:

Following the success of small-molecule high-throughput screening (HTS) in drug discovery, other large-scale screening techniques are currently revolutionizing the biological sciences. Powerful new statistical tools have been developed to analyze the vast amounts of data in DNA chip studies, but have not yet found their way into compound screening. In HTS, characterization of single-point hit lists is often done only in retrospect after the results of confirmation experiments are available. However, for prioritization, for optimal use of resources, for quality control, and for comparison of sc

APA, Harvard, Vancouver, ISO, and other styles

33

Wu, Patrick, Scott D. Nelson, Juan Zhao, et al. "DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions." Journal of the American Medical Informatics Association 28, no. 7 (2021): 1421–30. http://dx.doi.org/10.1093/jamia/ocab019.

Full text

Abstract:

Abstract Objective We developed and evaluated Drug-Drug Interaction Wide Association Study (DDIWAS). This novel method detects potential drug-drug interactions (DDIs) by leveraging data from the electronic health record (EHR) allergy list. Materials and Methods To identify potential DDIs, DDIWAS scans for drug pairs that are frequently documented together on the allergy list. Using deidentified medical records, we tested 616 drugs for potential DDIs with simvastatin (a common lipid-lowering drug) and amlodipine (a common blood-pressure lowering drug). We evaluated the performance to rediscover

APA, Harvard, Vancouver, ISO, and other styles

34

Banks, Martyn, Alastair Binnie, and Simon Fogarty. "High Throughput Screening Using Fully Integrated Robotic Screening." Journal of Biomolecular Screening 2, no. 3 (1997): 133–35. http://dx.doi.org/10.1177/108705719700200301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bandaru, Praveen, Dafeng Chu, Wujin Sun, et al. "High‐Throughput Drug Screening: A Microfabricated Sandwiching Assay for Nanoliter and High‐Throughput Biomarker Screening (Small 15/2019)." Small 15, no. 15 (2019): 1970078. http://dx.doi.org/10.1002/smll.201970078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Glickman, J. Fraser, Andres Schmid, and Sandrine Ferrand. "Scintillation Proximity Assays in High-Throughput Screening." ASSAY and Drug Development Technologies 6, no. 3 (2008): 433–55. http://dx.doi.org/10.1089/adt.2008.135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lopez-Peña, Ignacio, Jacob Chamoun, Joerg Martini, et al. "An optical microfluidic calorimeter for high-throughput drug screening." Biophysical Journal 121, no. 3 (2022): 415a. http://dx.doi.org/10.1016/j.bpj.2021.11.692.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Shu, Chih-Wen, Pei-Feng Liu, and Chun-Ming Huang. "High Throughput Screening for Drug Discovery of Autophagy Modulators." Combinatorial Chemistry & High Throughput Screening 15, no. 9 (2012): 721–29. http://dx.doi.org/10.2174/138620712803519734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kim, Hyun, Sehoon Jeong, Chiwan Koo, Arum Han, and Jaewon Park. "A Microchip for High-Throughput Axon Growth Drug Screening." Micromachines 7, no. 7 (2016): 114. http://dx.doi.org/10.3390/mi7070114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Sekhon, Bhagwant Kaur, Rebecca Heidi Roubin, Aaron Tan, Wing Keung Chan, and Daniel Man-Yuen Sze. "High-Throughput Screening Platform for Anticancer Therapeutic Drug Cytotoxicity." ASSAY and Drug Development Technologies 6, no. 5 (2008): 711–22. http://dx.doi.org/10.1089/adt.2008.148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rodríguez-Dévora, Jorge I., Bimeng Zhang, Daniel Reyna, Zhi-dong Shi, and Tao Xu. "High throughput miniature drug-screening platform using bioprinting technology." Biofabrication 4, no. 3 (2012): 035001. http://dx.doi.org/10.1088/1758-5082/4/3/035001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Ziegler, Christopher J., Adam P. Silverman, and Stephen J. Lippard. "High-throughput synthesis and screening of platinum drug candidates." JBIC Journal of Biological Inorganic Chemistry 5, no. 6 (2000): 774–83. http://dx.doi.org/10.1007/s007750000170.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Alonso-Padilla, Julio, and Ana Rodríguez. "High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery." PLoS Neglected Tropical Diseases 8, no. 12 (2014): e3259. http://dx.doi.org/10.1371/journal.pntd.0003259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Jiang, H., J. Shen, X. Luo, et al. "Structure-based high throughput virtual screening for drug discovery." Acta Crystallographica Section A Foundations of Crystallography 58, s1 (2002): c67. http://dx.doi.org/10.1107/s0108767302087706.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Pelczarska, Aleksandra, Florence Delie, Urszula Domańska, Pierre-Alain Carrupt, and Sophie Martel. "New high throughput screening method for drug release measurements." European Journal of Pharmaceutics and Biopharmaceutics 85, no. 1 (2013): 151–57. http://dx.doi.org/10.1016/j.ejpb.2013.02.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Zhang, Zhiyun, Ni Guan, Ting Li, Dale E. Mais, and Mingwei Wang. "Quality control of cell-based high-throughput drug screening." Acta Pharmaceutica Sinica B 2, no. 5 (2012): 429–38. http://dx.doi.org/10.1016/j.apsb.2012.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Coan, Kristin ED, Johannes Ottl, and Martin Klumpp. "Non-stoichiometric inhibition in biochemical high-throughput screening." Expert Opinion on Drug Discovery 6, no. 4 (2011): 405–17. http://dx.doi.org/10.1517/17460441.2011.561309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Jones, Amy J., and Vicky M. Avery. "Whole-organism high-throughput screening againstTrypanosoma brucei brucei." Expert Opinion on Drug Discovery 8, no. 5 (2013): 495–507. http://dx.doi.org/10.1517/17460441.2013.783816.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Degorce, François. "HTRF®: pioneering technology for high-throughput screening." Expert Opinion on Drug Discovery 1, no. 7 (2006): 753–64. http://dx.doi.org/10.1517/17460441.1.7.753.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Su, Xiaojing, Edmond W. K. Young, Heather A. S. Underkofler, Timothy J. Kamp, Craig T. January, and David J. Beebe. "Microfluidic Cell Culture and Its Application in High-Throughput Drug Screening." Journal of Biomolecular Screening 16, no. 1 (2010): 101–11. http://dx.doi.org/10.1177/1087057110386218.

Full text

Abstract:

Evaluation of drug cardiotoxicity is essential to the safe development of novel pharmaceuticals. Assessing a compound’s risk for prolongation of the surface electrocardiographic QT interval and hence risk for life-threatening arrhythmias is mandated before approval of nearly all new pharmaceuticals. QT prolongation has most commonly been associated with loss of current through hERG ( human ether-a-go-go related gene) potassium ion channels due to direct block of the ion channel by drugs or occasionally by inhibition of the plasma membrane expression of the channel protein. To develop an effici

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!